Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun;21(6):605.
doi: 10.3892/etm.2021.10037. Epub 2021 Apr 14.

Predictors of the response to nivolumab immunotherapy in the second or subsequent lines for metastatic non-small cell lung cancers

Sorin Săftescu  1 , Șerban Negru  1 , Simona Volovăț  2 , Dorel Popovici  1 , Vlad Chercota  3 , Simona Stanca  4 , Horea Feier  5 , Daniel Malita  6 , Radu Dragomir  7 , Constantin Volovăț  2
Affiliations

Predictors of the response to nivolumab immunotherapy in the second or subsequent lines for metastatic non-small cell lung cancers

Sorin Săftescu et al. Exp Ther Med. 2021 Jun.

Abstract

Checkpoint inhibitors represent the first therapeutic class to replace chemotherapy lines for the treatment of metastatic non-small cell lung cancer (NSCLC), due to improved overall survival and tolerability. Nivolumab, a fully human anti-programmed cell death-1 immunoglobulin G4 monoclonal antibody, is the first immune checkpoint inhibitor approved by the US Food and Drug Administration in 2014 for cases of metastatic melanoma and in 2015 for cases of squamous cell lung cancer and kidney cell cancer. The present study aimed to identify predictive markers (favorable or unfavorable) for time to treatment discontinuation using nivolumab in the second or subsequent line of therapy of metastatic NSCLC cases. Analysis of a group of 78 NSCLC patients treated with nivolumab allowed the identification of negative predictive markers, related to the presence of metastases (adrenal in men under 65 years, liver, brain and the number of metastatic sites) and the hematological profile (neutrophilia at the initiation of treatment and lymphocyte variation at 6 weeks of treatment).

Keywords: NSCLC; adrenal; immunotherapy; lymphocytes; metastases; nivolumab; non-small cell lung cancer; predictive.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
Individual variations in ALC at 6 weeks of treatment. ALC, absolute lymphocyte count.
Figure 2
Figure 2
Nivolumab immunotherapy treatment duration and actual status. Ended treatments indicated in orange.
Figure 3
Figure 3
RR for parameters with P<0.05. RR, risk ratio; ALC, absolute lymphocyte count; BRA, brain; PUL, pulmonary; HEP, hepatic; ADR, adrenal; OSS, osseous; ANC, absolute neutrophil count.
See this image and copyright information in PMC

References

    1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–264. doi: 10.1038/nrc3239. - DOI - PMC - PubMed
    1. Niezgoda A, Niezgoda P, Czajkowski R. Novel approaches to treatment of advanced melanoma: A review on targeted therapy and immunotherapy. Biomed Res Int. 2015;2015(851387) doi: 10.1155/2015/851387. - DOI - PMC - PubMed
    1. Bansal P, Osman D, Gan GN, Simon GR, Boumber Y. Recent advances in immunotherapy in metastatic NSCLC. Front Oncol. 2016;6(239) doi: 10.3389/fonc.2016.00239. - DOI - PMC - PubMed
    1. Gill DM, Agarwal N, Vaishampayan U. Evolving treatment paradigm in metastatic renal cell carcinoma. Am Soc Clin Oncol Educ Book. 2017;37:319–329. doi: 10.1200/EDBK_174469. - DOI - PMC - PubMed
    1. Wang C, Thudium KB, Han M, Wang XT, Huang H, Feingersh D, Garcia C, Wu Y, Kuhne M, Srinivasan M, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res. 2014;2:846–856. doi: 10.1158/2326-6066.CIR-14-0040. - DOI - PubMed